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ABSTRACT
Objectives Cross-sectional studies have shown a
strong association between Mycoplasma genitalium and
HIV infections. We previously reported that in a cohort of
female sex workers in Uganda, M genitalium infection at
baseline was associated with HIV seroconversion. Here
we examine the temporal association between the
M genitalium infection status shortly before HIV
seroconversion and HIV acquisition.
Methods A nested case-control study was conducted
within a cohort of women at high risk for HIV in
Kampala. Cases were those of women acquiring HIV
within 2 years of enrolment. For each of the 42 cases,
3 controls were selected from women HIV negative at
the visit when the corresponding case ﬁrst tested HIV
seropositive. The association between HIV acquisition
and M genitalium infection immediately prior to HIV
testing was analysed using conditional logistic
regression.
Results There was weak evidence of an association
between M genitalium infection and HIV acquisition
overall (crude OR=1.57; 95% CI 0.67 to 3.72,
aOR=2.28: 95% CI 0.81 to 6.47). However, time of
M genitalium testing affected the association (p value
for effect-modiﬁcation=0.004). For 29 case-control sets
with endocervical samples tested 3 months prior to the
ﬁrst HIV-positive result, M genitalium infection increased
the risk of HIV acquisition (crude OR=3.09; 95% CI
1.06 to 9.05, aOR=7.19; 95% CI 1.68 to 30.77),
whereas there was little evidence of an association
among the 13 case-control sets with samples tested at
an earlier visit (crude OR=0.30: 95% CI 0.04 to 2.51;
aOR=0.34; 95% CI 0.02 to 5.94).
Conclusions Our study showed evidence of a temporal
relationship between M genitalium infection and HIV
acquisition that suggests that M genitalium infection
may be a co-factor in the acquisition of HIV infection.
Mycoplasma genitalium infection is an emerging
sexually transmitted infection (STI). One-third of
nongonococcal nonchlamydial urethritis in men is
caused by M genitalium infection,1 and in women,
there is growing evidence that the infection is
associated with cervicitis, pelvic inﬂammatory
disease and reproductive health sequelae, although
further research is needed to provide conclusive
evidence.2
M genitalium infection is common, especially in
HIV-positive individuals where the prevalence
ranges between 5% and 33%.3–8 A systematic
review and meta-analysis found a twofold associ-
ation between prevalent M genitalium and HIV
infection (OR=2.01; 95% CI 1.44 to 2.79), with
an even stronger association among the nine
included studies from sub-Saharan Africa
(OR=2.57; 95% CI 2.05 to 3.22).3 We previously
reported that among female sex workers (FSW) in
Kampala, the prevalence of M genitalium infection
was 18% in HIV-positive and 12% in HIV-negative
women (adjusted OR 1.64, 95% CI 1.12 to 2.41,
p=0.01).9
The temporal relationship between M genitalium
infection and HIV infection can only be established
through longitudinal studies, and so far, there have
been very few such studies. Among FSW in Kenya,
HIV-positive women had a more than twofold
increased risk of acquiring M genitalium infection
compared with HIV-negative women (adjusted HR
2.17; 95% CI 1.27 to 3.71, p=0.01).10 A prospect-
ive study among women attending family planning
services in Zimbabwe and Uganda found that the
risk of acquiring HIV infection was more than
twice higher in women infected with M genitalium
prior to HIV detection (adjusted OR=2.42; 95%
CI 1.01 to 5.80).11 In our cohort of women with
high-risk behaviour in Kampala, women diagnosed
with M genitalium infection at the baseline visit
had a more than twofold higher risk of HIV sero-
conversion during follow-up time than those who
were free of M genitalium infection (adjusted
HR=2.28, 95% CI 1.15 to 4.52).12 The latter
ﬁnding prompted us to conduct a nested case-
control study to examine the M genitalium infec-
tion status shortly before seroconversion in cases
and at an equivalent time-point in matched controls
in order to investigate the temporal association
between M genitalium infection and subsequent
HIV acquisition.
METHODS
Study population and study procedures
Between April 2008 and April 2009, a cohort of
1027 women involved in high-risk sexual behavi-
our was recruited in Kampala. The establishment of
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this cohort and the study procedures have been reported previ-
ously.12 13 In brief, self-reporting FSW and women employed in
entertainment facilities located in red-light areas were enrolled
and invited to attend 3-monthly visits at the study clinic in
Kampala. At every visit, women were interviewed about socio-
demographic characteristics, risk behaviour, reproductive health
history and symptoms of STIs. Blood was tested for HIV, herpes
simplex virus type 2 (HSV2) and syphilis. Two endocervical spe-
cimens were collected, one for the immediate diagnosis of gono-
coccal and chlamydial infection and one for later diagnosis of M
genitalium infection. One high vaginal specimen was inoculated
for culture of Trichomonas vaginalis, another for the detection
of bacterial vaginosis and Candida infection. Symptomatic STIs
were treated syndromically and asymptomatic STIs were treated
as soon as laboratory results became available. From the second
year of follow-up onwards, due to ﬁnancial constraints, genital
sample collection was reduced from 3-monthly to 6-monthly,
whereas blood tests and epidemiological data were collected
every 3 months, as before. As testing for M genitalium infection
was done some 2–3 years after sample taking, none of the
women were speciﬁcally treated for M genitalium infection at
the time of the visit.
The current analyses use data up to 31st March, 2011. Cases
were women who were HIV negative at enrolment and acquired
HIV before the end of follow-up. For each case, three controls,
individually matched by age group (15–24, 25–34, >35 years),
were selected randomly from women who were HIV negative
after a similar length of time in the cohort as the cases. For
instance, if a case was found to be HIV infected at the 3rd quar-
terly visit, controls were selected among the women who were
still HIV negative at their 3rd quarterly visit. M genitalium
testing was performed on endocervical samples collected at the
last HIV-negative visit for cases and at equivalent visits for con-
trols. If no sample was collected at the relevant visit for the case
or for any of their controls, the most recent available sample
from an earlier visit was taken for the case and all three con-
trols. For instance, if HIV seroconversion was detected at the
month 9 visit and no sample was available at the month 6 visit
either from the case or from any of their selected controls, the
sample at the month 3 visit was tested for M genitalium infec-
tion for the case and all three controls.
Laboratory procedures
Serum specimens were ﬁrst tested for HIV-1 infection using a
rapid test, the Abbott Determine HIV-1/2. Positive samples were
conﬁrmed by two ELISA tests (Vironostika Uniform II plus O
and Murex HIV 1.2.O). Antibodies against HSV-2 were tested
for using an HSV-speciﬁc IgG ELISA (Kalon Biologicals Ltd).
Syphilis was tested with the Rapid plasma reagin (RPR) assay
and the Treponema pallidum Hemagglutination assay (TPHA)
(Biotec Laboratories Ltd). Neisseria gonorrhoeae and Chlamydia
trachomatis were diagnosed using the Amplicor PCR test
(Roche Diagnostic Systems Inc., Branchburg, New Jersey) and
Trichomonas vaginalis was detected using the commercial
culture kit (InPouch TV, BioMed Diagostics, White City,
Oregon, USA). Microscopy on a Gram-stained vaginal specimen
was performed for bacterial vaginosis (using Nugent’s criteria)
and Candida infection. All these tests were performed at the
laboratories of the MRC/UVRI Research Unit in Entebbe.
The endocervical specimens collected for the M genitalium
studies were stored at −20°C at the MRC/UVRI laboratories
within 12 h of collection. Testing for M genitalium infection was
carried out at the Centre for HIV and STIs, National Health
Laboratory Service in Johannesburg, using a commercially
available Real-TM PCR assay (Sacace Biotechnologies, Como,
Italy). Details of this PCR test were reported previously.9
Statistical analysis
Data were double entered in Access and analysed using STATA
V.11.0 (Stata Inc., College Station, Texas, USA). The OR
and 95% CI for the association between HIV acquisition and
M genitalium infection were estimated using conditional logistic
regression to allow for the individual matching of cases and con-
trols. A multivariable analysis was conducted to adjust the asso-
ciation of HIV acquisition and M genitalium infection for
confounding, with factors retained in the ﬁnal model if their
inclusion changed the OR for the association of HIV and
M genitalium infections substantially (>20%) due to the rela-
tively small number of events.14 For time-dependent factors, the
data were from the visit for which the M genitalium result was
available. For non-time-dependent factors, baseline data were used.
Although participants were scheduled at 3-monthly visits,
endocervical samples were not always available from the visit
3 months prior to HIV detection either because the participant
did not attend or no genital samples had been collected. Therefore,
a multivariable analysis stratiﬁed by time of M genitalium testing
(3 months vs ≥6 months prior to HIV seroconversion) was con-
ducted to investigate the relationship between HIV seroconver-
sion and time of M genitalium infection.
Ethical considerations
Written informed consent, or witnessed ﬁngerprint consent in
case of illiteracy, was obtained from all participants before enrol-
ment. The study was approved by the Science and Ethics
Committee of the Ugandan Virus Research Institute, by the
Uganda National Committee for Science and Technology and by
the ethics committee of the London School of Hygiene and
Tropical Medicine.
RESULTS
Among the 1027 participants, 646 were HIV-negative at enrol-
ment (HIV-prevalence 37%). Between 1 April 2008 and 31
March 2011, 42 women acquired HIV, giving an HIV incidence
rate of 3.66/100 person years (pyr) (95% CI 2.71 to 4.96/
100 pyr).
The study population for the nested case-control study con-
sisted of these 42 cases and 126 matched controls. For 29 case-
control sets, M genitalium testing was carried out at the visit
3 months prior to the ﬁrst HIV-positive test result, while for the
remaining 13 sets, testing was done at an earlier visit (nine sets
at 6 months, two sets at 9 months, one set at 15 months and
one set at 18 months prior to HIV detection).
The 42 cases and 126 controls were similar with respect to
marital status, level of education, income related to sex work,
and sexual risk behaviour in terms of number of sexual partners
and condom use with paying clients (table 1). Cases were more
likely to report use of illicit drugs and alcohol during follow-up
and to be classiﬁed as problem drinkers at enrolment than their
corresponding controls. HSV2, N gonorrhoeae and bacterial
vaginosis were more prevalent at the visit prior to the HIV posi-
tive test among cases than among controls and this difference
was statistically signiﬁcant. M genitalium infection was detected
in 10 (24%) of cases and in 21 (17%) of controls. On univari-
able analysis, there was some evidence of an association
between prior M genitalium infection and HIV acquisition
(OR=1.57; 95% CI 0.66 to 3.72). The association became
stronger after adjusting for confounders (adjusted OR=2.28;
95% CI 0.81 to 6.47) (table 2).
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Table 1 Characteristics of HIV seroconverters (cases) and their age-matched controls
Total study population
Cases n (%) Controls n (%)
Crude OR (95% CI)N=42 N=126
Socio demographic factors
Age (matching variable)
14–24 years 26 (62%) 78 (62%) –
25–34 years 15 (36%) 45 (36%) –
>35 years 1 (2%) 3 (2%) –
Marital status*
Formerly married 29 (69) 71 (56) 1
Currently married 5 (12) 23 (18) 0.52 (0.17 to 1.54)
Single 8 (19) 32 (25) 0.59 (0.23 to 1.52)
Level of education†
Primary completed or higher 24 (57) 73 (58) 1
Primary uncompleted or no education 18 (43) 53 (42) 1.03 (0.53 to 2.01)
Source of income*
Sex work only 15 (36) 26 (21) 1
Sex work and other 22 (52) 87 (69) 0.41 (0.18 to 0.94)
No sex work 5 (12) 13 (10) 0.61 (0.17 to 2.19)
Behavioral factors
Alcohol use defined by CAGE score†
Not drinking/not problem drinking 11 (26) 62 (49) 1
Problem drinking 31 (74) 64 (51) 2.90 (1.31 to 6.42)
Total study population
Cases n (%) Controls n (%) Crude OR (95% CI)
No. of sexual partners in last month*
<5 17 (40) 66 (52) 1
5–19 11 (26) 29 (23) 1.42 (0.59 to 3.44)
20–49 7 (17) 22 (18) 1.33 (0.46 to 3.82)
50+ or can’t remember 7 (17) 9 (7) 2.96 (0.96 to 9.15)
Paying clients in last month*
No 8 (19) 22 (17) 1
Yes 34 (81) 104 (83) 0.90 (0.36 to 2.23)
Condom use with paying clients in last month*,‡
Consistent 14 (41) 51 (49) 1
Inconsistent 20 (59) 53 (51) 1.39 (0.62 to 3.11)
Intravaginal cleansing in past 3 months*
Cleansing using soap 19 (45) 62 (49) 1
Cleansing using water only 18 (43) 60 (48) 0.96 (0.47 to 1.97)
No cleansing 5 (12) 4 (3) 3.69 (0.95 to 14.25)
Reproductive health
Currently pregnant*
No 38 (90) 111 (88) 1
Yes 4 (10) 15 (12) 0.78 (0.25 to 2.48)
Use of hormonal contraceptives in past 3 months*,§
None 19 (50) 64 (58) 1
Oral 5 (13) 13 (12) 1.29 (0.41 to 4.03)
Injectable 14 (37) 34 (31) 1.40 (0.61 to 3.21)
Reproductive tract infections
Mycoplasma genitalium*
Negative 32 (76) 105 (83) 1
Positive 10 (24) 21 (17) 1.57 (0.67 to 3.72)
Herpes simplex virus type 2 serology*
Negative 3 (7) 48 (38) 1
Positive 39 (93) 78 (62) 7.89 (2.32 to 26.8)
Syphilis*
RPR−TPHA− 31 (74) 102 (81) 1
RPR−TPHA+ 2 (5) 11 (9) 0.58 (0.12 to 2.70)
RPR+TPHA+ 9 (21) 13 (10) 2.15 (0.88 to 5.27)
Continued
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The time of M genitalium testing affected the observed associ-
ation with HIV acquisition (p value for effect-modiﬁcation=
0.004). Therefore, the association was re-evaluated separately in
case-control sets with and without M genitalium test results for the
visit prior to HIV seroconversion. For the 29 case-control sets with
endocervical samples tested 3 months prior to HIV detection
(or equivalent visit for controls), there was evidence that M
genitalium increased the risk of HIV acquisition (crude
OR=3.09; 95% CI 1.06 to 9.05, adjusted OR=7.19; 95%CI
1.68 to 30.77), whereas for the 13 case-control sets with endocer-
vical samples tested at an earlier visit, there was no evidence of
association with HIV acquisition (crude OR=0.30; 95%CI=0.04
to 2.51; adjusted OR=0.34; 95%CI 0.02 to 5.94) (table 2).
DISCUSSION
Our study investigated the temporal relationship between pre-
existing M genitalium infection and HIV acquisition among
women at high risk for HIV in Kampala. We found evidence
that women diagnosed with M genitalium infection were at
threefold higher odds of acquiring HIV during the 3 months
following M genitalium detection, whereas there was little evi-
dence of an association among the 13 case-control sets with
samples tested at an earlier visit.
Our results are consistent with the results of the case-control
study of Mavedzenge et al., which had similar time intervals
between M genitalium and HIV tests (adjusted OR=2.42; 95%
CI 1.01 to 5.80).11 The difference in strength of association
between the studies may be due to chance, may reﬂect the dif-
ference in study populations (high risk vs general population) or
may be due to residual confounding in either study.
The association with HIV acquisition is biologically plausible.
After inoculation of M genitalium in the urogenital tract, bacter-
ial toxins disrupt the mucosal barrier.15 More importantly, the
host cell responds to the infection with a prominent
Table 2 Association between prior infection with Mycoplasma genitalium and HIV seroconversion
Cases n (%) Controls n (%) Crude OR (95% CI) Adjusted OR* (95% CI)
Total study population
M genitalium p=0.30 p=0.10
Negative 32 (76) 105 (83) 1 1
Positive 10 (24) 21 (17) 1.57 (0.67 to 3.72) 2.28 (0.81 to 6.47)
M genitalium tested at visit 3 months prior to first HIV-positive result
M genitalium p=0.04 p=0.002
Negative 20 (69) 75 (86) 1 1
Positive 9 (31) 12 (14) 3.09 (1.06 to 9.05) 7.19 (1.68 to 30.77)
M genitalium tested at visit >3 months prior to first HIV-positive result
M genitalium p=0.27 p=0.38
Negative 12 (92) 30 (77) 1 1
Positive 1 (8) 9 (23) 0.30 (0.04 to 2.51) 0.34 (0.02 to 5.94)
*Adjusted for problem drinking at baseline and source of income; p value for effect-modification with time=0.01.
Table 1 Continued
Total study population
Cases n (%) Controls n (%)
Crude OR (95% CI)N=42 N=126
Neisseria gonorrhoeae*,¶
Negative 25 (76) 95 (96) 1
Positive 8 (24) 4 (4) 6.00 (1.81 to 19.92)
Chlamydia trachomatis*,¶
Negative 30 (91) 97 (98) 1
Positive 3 (9) 2 (2) 7.24 (0.73 to 72.04)
Trichomonas vaginalis*,**
Negative 29 (83) 87 (86) 1
Positive 6 (17) 14 (14) 1.00 (0.31 to 3.26)
Candida albicans*,¶
Negative 32 (97) 92 (93) 1
Positive 1 (3) 7 (7) 0.40 (0.05 to 3.46)
Bacterial vaginosis*,¶
Negative/intermediate 8 (24) 55 (56) 1
Positive 25 (76) 44 (44) 3.97 (1.55 to 10.19)
*At same visit as M genitalium was tested.
†At baseline visit.
‡Among women with paying clients in past month.
§Among not pregnant women.
¶Missing for 9 cases and 27 controls.
**Missing for 7 cases and 25 controls.
RPR, Rapid plasma regain; TPHA, Treponema pallidum Hemagglutination assay
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inﬂammatory reaction, which triggers cytokine production and
increases presence and activation of HIV susceptible cells.16–18
The association was affected by the time between M genitalium
testing and HIV acquisition. The most plausible explanation is
that earlier M genitalium infection may have cleared spontan-
eously by the time the woman was exposed to HIV. We reported
earlier that in our cohort, among the women diagnosed with
M genitalium infection at enrolment, 55% spontaneously
cleared the infection within 3 months and 83% within
6 months.19
Although M genitalium infection was not speciﬁcally treated
at the time of visit, the infection may have cleared because of
treatment with antibiotics administered for other STIs or
health conditions, and this may have been differential in the
two time groups. However, only 14% of the women with
recent M genitalium infection and none of those with earlier
M genitalium infection in our study had records showing
that they had received treatment likely to be effective against
M genitalium (doxycycline, ciproﬂoxacin or erythromycin).
An alternative hypothesis for the discrepancy between both
time groups is that the disruptive and inﬂammatory processes
caused by mycoplasma infections may be more abundant during
the acute stage of the infection and become less important later
on. Due to ﬁnancial constraints, we were not able to test for
M genitalium infection at all consecutive visits prior to HIV
seroconversion, and so it was not possible to disentangle
whether the detected M genitalium infections were either early
(acute) or rather longer lasting persistent infections.
Limitations of our study were (i.) the small sample size, result-
ing in wide CIs for the estimated association and (ii.) the large
number of potential confounding factors compared with the
small number of cases (42). Regression models should be used
with a minimum of 10 outcome events per predictor variable.14
Therefore, it was decided to include only the factors with the
strongest confounding effect (source of income, alcohol use
deﬁned by CAGE, HSV-2 infection), besides the matching vari-
able age, to keep the robustness of the regression model intact.
However, the magnitude of the point estimate after adjust-
ment for confounding is compelling, and calls for larger longitu-
dinal studies to conﬁrm the ﬁndings.
In conclusion, our ﬁndings suggest that M genitalium infec-
tion may be a co-factor in HIV acquisition. The consistent
results obtained from low-11 and high-risk women in a similar
setting lend support to the generalisability of the ﬁndings.
Control measures for M genitalium infection should be consid-
ered, especially in populations at high risk for HIV.
Key messages
▸ Infection with Mycoplasma genitalium immediately prior to
HIV seroconversion increased the risk of HIV acquisition
among Ugandan female sex workers.
▸ There was little evidence of an association between M
genitalium infection and HIV acquisition if M genitalium was
tested ≥6 months prior to time of ﬁrst HIV test.
▸ Screening for and treatment of M genitalium infection
should be considered as part of the HIV prevention strategy,
especially in populations at high risk.
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